Home Suda Pharmaceuticals Ltd (ASX: SUD)

Suda Pharmaceuticals Ltd (ASX: SUD)

    Insight into Oro-Mucosal Drug Delivery Leader, SUDA Pharmaceutical’s FY19 Annual Report

    Australian-headquartered global pharmaceutical leader, SUDA Pharmaceuticals Limited (ASX: SUD) is engaged in the reformulation of existing drugs and provision of medication via the oral...
    SUDA

    SUDA Pharmaceuticals Progressing Well in 2019 with Significant Regulatory and Patent Approvals

    Australia’s leading oro-mucosal drug delivery company, SUDA Pharmaceuticals Ltd (ASX: SUD) develops low-risk, easy-to-use oral sprays using its OroMist® technology to reformulate existing medications....

    SUDA’s OroMist® Technology Revamping Pharmaceutical Industry

    Australian headquartered pharmaceutical giant, SUDA Pharmaceuticals Ltd (ASX: SUD) is an oro-mucosal drug delivery leader, engaged in the reformulation of existing medications into oral...
    Oro-Mucosal Drug Delivery Leader, SUDA Pharmaceuticals Releases Preliminary Final Report

    Oro-Mucosal Drug Delivery Leader, SUDA Pharmaceuticals Releases Preliminary Final Report

    Drugs intake in the form of pills, capsules, and tablets are not the most efficient ways of taking medicine, because only about 25% of...

    SUDA Pharmaceuticals Reformulating Billion-Dollar Drugs for Oral Delivery

    Australia’s leading oro-mucosal drug delivery company, SUDA Pharmaceuticals Ltd (ASX: SUD) produces reliable oral sprays by using its proprietary OroMist® technology to redevelop the...

    SUDA Makes Speedy Progress with its Robust Product Pipeline

    SUDA Pharmaceuticals Ltd (ASX: SUD) is transforming the drug delivery technology to improve the lifestyle and health of the global community by offering innovative...
    SUDA’s Science

    SUDA’s Science Advisory Board Member, Dr Richard Franklin Joins as Project Director of Anagrelide...

    SUDA Pharmaceuticals Ltd (ASX: SUD), an oro-mucosal drug delivery company headquartered in Perth, focusses on developing low-risk oral sprays using its proprietary OroMist® oro-mucosal...
    SUDA

    SUDA welcomes Australian Government’s Initiatives to Foster Medical Marijuana Industry

    To increase the bioavailability of administered medications, Australian-headquartered SUDA Pharmaceuticals Ltd (ASX: SUD) is reformulating medications into an oral spray. The delivery of medications...
    SUDA Pharmaceuticals: Pharmacy And Pharmacology Journal Publishes Impressive ZolpiMistTM Clinical Study Results

    SUDA Pharmaceuticals: Pharmacy And Pharmacology Journal Publishes Impressive ZolpiMistTM Clinical Study Results

    SUDA Pharmaceuticals Ltd (ASX: SUD) is an oro-mucosal drug delivery company that is reformulating medication into an oral spray to improve the bioavailability of...

    SUDA’s June Quarterly Report Out On ASX; A Look At Its Business And Technology

    On 31 July 2019, SUDA Pharmaceuticals Ltd (ASX: SUD), an oro-mucosal drug delivery firm, has released its June quarterly updates on the ASX. SUDA...

    Recent News